Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Li, Yin ^a   Pan, Ke ^a   Liu, Li Zhi ^a   Li, Yong Qiang ^a   Gu, Mo Fa ^a   Zhang, Hua ^b   Shen, Weixi ^c   Xia, Jian Chuan ^a   Li, Jian Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISTANT METASTASIS; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; CISPLATIN; CYTOKINE-INDUCED KILLER CELLS; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS;

EID: 84939196976     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130620     Document Type: Article

References (29)

1. Chan AT, Teo P, Leung TW, Johnson PJ. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer, 1998; 82: 1003-1012. PMID: 9506343
2. Fandi A, Atum M, Azli N, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol, 1994; 21: 382-397. PMID: 8209270
3. Wang ZJ, Ramcharan S, Love EJ. Cancer mortality of Chinese in Canada. Int J Epidemiol, 1989; 18: 17-21. PMID: 2722361
4. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 2002; 95:2516-2523. PMID: 12467065
5. Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, Carboplatin, and Gemcitabine in MetastaticNasopharyngeal Carcinoma: a Phase II trial using a triplet combination. Cancer, 2005; 103: 569-575. PMID: 15611975
6. Poon D, Chowbay B, Cheung YB, Leong SS, Tan EH. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer, 2005; 103: 576-81. PMID: 15612023
7. Gu MF, Liu LZ, He LJ, Yuan WX, Zhang R, Luo GY, et al. Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma. Int J Cancer, 2013; 32: 215-23.
8. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med, 1991; 174: 139-49. PMID: 1711560
9. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 1985; 313: 1485-1492. PMID: 3903508
10. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, S et al. Adoptive immunotherapyto lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet, 2000; 356:802-807. PMID: 11022927
11. Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol, 2013; 20: 4305-4011. doi: 10.1245/s10434-013-3144-x PMID: 23892527
12. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother, 2008; 31: 63-71. PMID: 18157013
13. Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother, 2012; 61: 2251-2259. doi: 10.1007/s00262-012-1289-2 PMID: 22674056
14. Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother, 2012; 61: 2125-2133. doi: 10.1007/s00262-012-1260-2 PMID: 22581306
15. Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res, 2012; 18: 1751-9. doi: 10.1158/1078-0432.CCR-11-2442 PMID: 22275504
16. Su X, Zhang L, Jin L, Ye J, Guan Z, Chen R, et al. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother Radiopharm, 2010; 25: 465-470. doi: 10.1089/cbr.2010.0762 PMID: 20701541
17. Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother, 2012; 35: 189-95. doi: 10.1097/CJI.0b013e318241d9de PMID: 22306907
18. National Cancer Institute. Cancer Therapy Evaluation Program,Common Toxicity Criteria. Version 2.0. Bethesda, MD: 1999.
19. World Health Organization. International Classification of Tumors: Histological Typing of Upper Respiratory Tract Tumors. Geneva: 1991.
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000; 92: 205-16. PMID: 10655437
21. Chang JT, Ko JY, Hong RL. Recent advances in the treatment of nasopharyngeal carcinoma. J Formos Med Assoc 2004; 103: 496-510. PMID: 15318271
22. Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharygeal carcinoma:report of phase II study. Ann Oncol, 2002; 13:1252-1258. PMID: 12181249
23. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M. Large-scale expansion of Cd3 (+)Cd56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunother, 2002; 51: 440-448. PMID: 12202905
24. Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immuno, 1996; 169: 85-90. PMID: 8612299
25. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol, 2004; 10: 1146-51. PMID: 15069715
26. Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother, 2008; 31: 132-47. doi: 10.1097/CJI.0b013e31815b69c8 PMID: 18481383
27. Comoli P1, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol, 2005; 23: 8942-9. PMID: 16204009
28. Comoli P1, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinomat al. Ann Oncol, 2004; 15: 113-7. PMID: 14679129
29. Chia WK, Teo M, Wang WW, ee B, Ang SF, Tai WM, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther, 2014; 22: 132-9. doi: 10.1038/mt.2013.242 PMID: 24297049